Help save lives this holiday season
Prostate cancer statistics
Prostate cancer is the most common cancer among Canadian men (excluding non-melanoma skin cancers). It is the 3rd leading cause of death from cancer in men in Canada.
To provide the most current cancer statistics, statistical methods are used to estimate the number of new cancer cases and deaths until actual data become available.
Incidence and mortality
Incidence is the total number of new cases of cancer. Mortality is the number of deaths due to cancer.
It is estimated that in 2016:
- 21,600 men will be diagnosed with prostate cancer. This represents 21% of all new cancer cases in men in 2016.
- 4,000 men will die from prostate cancer. This represents 10% of all cancer deaths in men in 2016.
- On average, 59 Canadian men will be diagnosed with prostate cancer every day.
- On average, 11 Canadian men will die from prostate cancer every day.
Incidence rate (for every 100,000 males)*
Death rate (for every 100,000 males)*
5-year net survival (estimates for 2006–2008)
*Age-standardized to the 2011 Canadian Standard Population. Age-standardization is a statistical method that removes the effect of age on the calculated rate. It allows rates to be compared over time or across provinces and territories.
Trends in prostate cancer
In Canada, the incidence rate of prostate cancer peaked in 1993 and again in 2001. Each of these peaks was followed by a decline. These peaks are compatible with two waves of intensified screening activity using the prostate-specific antigen (PSA) test. Since 2001, the incidence rate has generally been declining
The mortality rate for prostate cancer rose slowly from 1987 to 1997 and has been declining since. The decline likely reflects improved treatment.
Chances (probability) of developing or dying from prostate cancer
Based on 2010 estimates, about 1 in 8 Canadian men is expected to develop prostate cancer during his lifetime and 1 in 27 will die from it.
For more information, go to the Canadian Cancer Statistics publication.
Clinical trial discovery improves quality of life
A clinical trial led by the Society’s NCIC Clinical Trials group found that men with prostate cancer who are treated with intermittent courses of hormone therapy live as long as those receiving continuous therapy.